VOOPOO
20.4.2022 06:10:47 CEST | Business Wire | Press release
VOOPOO, leading vape brand, along with its sister brand ZOVOO, is looking forward to meeting you at the National Convenience Show Birmingham 2022 on April 25-27.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220414005472/en/
The National Convenience Show Birmingham is not only the largest retail show in the UK, but also the most professional world-class event in the world’s retail industry. This year, the event will gather 1,000+ global vendors to share cutting-edge consumer insights and commercial trends, and discuss hot topics such as technology, sustainable development, food hygiene and health, and social media. 90,000+ professional visitors are expected to visit the event.
As the leader of vape technology, VOOPOO and ZOVOO will feature three new products of the year in a 25sqm uniquely-designed booth and showcase new technological breakthroughs and smarter experience in the vape industry. On this occasion, VOOPOO looks forward to establishing connections with more excellent partners, peer brands and users, to jointly develop the market.
ARGUS GT 2, a member of VOOPOO’s high-end ARGUS series and the first MOD product in 2022, will be exhibited at the event. While inheriting the classic style of ARGUS GT, ARGUS GT 2 also provides a fully upgraded professional vape experience, a masculine aesthetic design and an improved collision-proof performance to satisfy massive clouds lovers and those vapers who pursue intensive explosion, high performance and high durability. It is poised to define a new height of user experience.
Powerful TPP vape platform, high power and massive clouds
ARGUS GT 2 is compatible with VOOPOO’s universal TPP vape platform, and with a maximum output power of 200W. The moment the ignition button is pressed, massive clouds will volcanically spew out, bringing users the ultimate enjoyment of taste and the strongest visual pleasure. In addition, with a 200W stable output, users are allowed to enjoy the luxurious experience in a leisurely manner.
Top water, dust and collision-proof body to withstand extreme outdoor scenarios
ARGUS GT 2 has obtained the IP68 rating, the highest rating of protection against water, dust and collision. After thousands of tests, the team for ARGUS GT 2 has created a powerful double-layer waterproof, dust-proof, frost-proof, and collision-proof body that can withstand various extreme outdoor environments like temperatures ranging from minus 20°C to 60°C without affecting its performance. Such a hard and durable ARGUS GT 2 will definitely become the best choice for outdoor vapers.
Innovative volcano crater design to guarantee both massive clouds and leak-proofness
Featured with massive clouds, ARGUS GT 2 comes with the MAAT TANK NEW, which has the unique two-way volcano crater airflow design that can increase the airflow rate by 60% and produce thicker clouds at a higher speed; at the same time, it can better drain the condensed liquid to the isolation section at the bottom, so as to create the ultimate leak-proof experience.
Top GENE.TT 2.0 chip to enable new experience of all-scenario intelligence
ARGUS GT 2 features GENE.TT 2.0 technology and is equipped with an upgraded smart chipset which can automatically match power, and supports multi-mode switching between Smart, RBA, Turbo and TC, allowing vapers to easily control their daily experience. In addition, it adopts a hidden 3A TYPE-C fast charging design, and the charging speed is also improved by 30%. VOOPOO products are rich in color and unique in design. ARGUS GT 2 to be displayed this time is no exception. It will offer five new colors including carbon fiber grey, lime green, and dark blue. This perfect fusion of technology and design will surely bring another surprise to the industry.
As a disruptor in the POD market, ZOVOO will bring DRAGBAR 600s, the first disposable vape with a light bar. The DRAGBAR series have been loved by global users since their launch. The innovative use of ethyl maltol to provide the sweetness in e-liquid can effectively avoid sugar addiction which causes harm to the human body, and are popular among vapers who favor sugar-free and low-sugar e-liquid. What kind of disruptive technology will the DRAGBAR 600s present at the show? In addition to ARGUS GT 2, what new surprises will VOOPOO's other two mysterious new products bring to the industry? Let's wait and see at Booth E20 of National Convenience Show Birmingham 2022 from April 25 to 27!
About VOOPOO
Founded in 2017, VOOPOO has rapidly grown and recognized by vapers from around the world with its DRAG series. VOOPOO is a high-tech enterprise integrating R&D, design, production and brand operation. It has four flagship product series: DRAG, VINCI, ARGUS and V Series, altogether providing consumers with a safe, reliable and diverse all-scenario product ecosystem. Currently, VOOPOO products are sold in more than 70 countries and regions in North America, Europe and Asia. VOOPOO will pursue long-term value and strengthen exchanges and cooperation in technology, brand, and supply chain, and promote the innovation and development of the vape industry. For more information, please visit https://www.voopoo.com/ and follow our Instagram, Facebook and TikTok.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005472/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom